AstraZeneca’s vaccine suspended in multiple EU nations over blood clot concerns

Source: insta_photos, Shutterstock

Summary

  • Following reports of serious events related to blood coagulation, some EU nations have temporarily terminated AstraZeneca’s COVID-19 vaccine administration.
  • So far, no relation has been determined between the COVID-19 jab and the side effect.
  • The UK regulator stated that there was no evidence that the COVID-19 vaccine of AstraZeneca had triggered problems.

With rising concerns over Oxford-AstraZeneca’s COVID-19 vaccine’s side effects, some European countries temporarily suspended the vaccine’s use. Some media reports mention that patients have developed serious side effects related to thromboembolic events after receiving the vaccine shot.

Stockbakery | Megapixl.com

Let us delve deeper and discuss this in detail-

Denmark became the first European nations to temporary suspend Oxford-AstraZeneca’s vaccine, subsequent to the reporting serious cases of blood clots among people who had received the vaccine. Some media reports mention that as per the European Medicines Agency (EMA), 22 cases of blood coagulation had been reported in over three million people vaccinated in the EEA (European Economic Area) as of 9 March 2021.

On 11 March 2021, Denmark, Norway, and Iceland temporarily halted the use of AstraZeneca's vaccine, as the manufacturer and the medicines regulator asserted the COVID-19 jab was safe.

Austria had also suspended using a batch of Oxford-AstraZeneca COVID-19 shots after the death of a nurse of 49 year due to severe blood coagulation issues after a few days of obtaining the vaccine.

Moreover, four other European nations, including Estonia, Latvia, Lithuania, and Luxemburg, have also suspended COVID-19 vaccines administration from the batch sent to 17 European countries and comprises almost one million vaccines.

Source: © Mikemareen| Megapixl.com

ALSO READ: Italy to become the first EU nation to manufacture Russia’s Sputnik V vaccine

No connection found between vaccine and blood clots

The countries have taken this move as a precautionary step. However, it has not been determined whether there is any link between the jab and the blood clots.

As per the EU medicines regulator, there is no indication that Oxford-AstraZeneca’s COVID-19 jab is linked with the increased risk of blood coagulation.

The health regulator of the UK, the Medicines and Healthcare products Regulatory Agency (MHRA), stated that there was no evidence that the COVID-19 vaccine had caused problems. The MHRA emphasised that individuals should go and get vaccinated when requested to do so.  Phil Bryan of the MHRA commented-

It is highlighted that nearly 30 individuals have reported thromboembolic incidents so far among the 5 million people in Europe who have received Oxford-AstraZeneca’s jab. The British-Swedish multinational player AstraZeneca stated that it had extensively evaluated the safety of the COVID-19 vaccine in clinical trials.

DO READ: Merck/Ridgeback’s COVID-19 oral drug shows promising Phase 2 data


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK